“We believe UG Healthcare Corp can record another 5x net profit jump in FY6/21F, on the back of strong global glove demand due to the Covid-19 pandemic,” he adds.
The best is yet to come for UG Healthcare, says CGS-CIMB Securities who is maintaining its “add” or “buy” call on the counter at a revised target price of $4.80.
This is up $1.80 from its previous $3.00 call and is believed to have a 95.9% upside from the counter’s $2.45 price on September 7, analyst Ong Khang Chuen explains.
